Viewing Study NCT01471990



Ignite Creation Date: 2024-05-06 @ 12:01 AM
Last Modification Date: 2024-10-26 @ 10:43 AM
Study NCT ID: NCT01471990
Status: COMPLETED
Last Update Posted: 2012-08-29
First Post: 2011-11-09

Brief Title: Effect of PACAP38VIP on Migraineurs Measured by Magnetic Resonance
Sponsor: Glostrup University Hospital Copenhagen
Organization: Glostrup University Hospital Copenhagen

Study Overview

Official Title: The Effect of PACAP38 and VIP on Migraine Patients Assessed by a 3-Tesla MR Scanner
Status: COMPLETED
Status Verified Date: 2012-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to examine and compare the effect of pituitary adenylate cyclase-activating polypeptide-38 PACAP38 and vasoactive intestinal polypeptide VIP on intracranial arteries and neuronal activity in patients with migraine without aura using a high resolution magnetic resonance imaging MRI including MR angiography MRA and functional MRI fMRI

MRA will be used to detect changes in intracranial artery circumferences before and after PACAP38 and VIP

fMRI will be used oo detect changes in blood-oxygenation-level-dependent-signal BOLD-signal

PACAP38 but not VIP induces migraine like attacks in migraine patients The migraine specific drug sumatriptan will be given to relieve pain and the effect will also be registered using MRA and fMRI
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None